Trials / Unknown
UnknownNCT01776489
Evaluation of the Sphingolipid Metabolite S1P as a Novel Biomarker in Food Allergy
The Role of Sphingosine-1-phosphate in Food Allergy - Biomarker for Disease Severity and Anaphylaxis Outcome
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 70 (estimated)
- Sponsor
- Medical University of Vienna · Academic / Other
- Sex
- All
- Age
- 12 Months – 17 Years
- Healthy volunteers
- Not accepted
Summary
Food allergies represent an increasing health concern in the industrialized countries and especially affect pediatric patients. In this population adverse reactions against food compounds can lead to anaphylactic reactions. Despite substantial research efforts, clinical markers predicting disease severity and symptoms are missing to date. Recent studies have revealed that sphingolipids, especially sphingosine-1-phosphate (S1P), play an essential role in allergy. It was reported that asthmatic patients have higher S1P levels in bronchiallavage fluids after allergen challenge. First experimental studies revealed a correlation of S1P and the outcome of anaphylaxis. Furthermore, we have shown in our recent mouse study that S1P homeostasis is pivotal for food allergy induction and effector cell response. Therefore, it is the aim of the presented pilot project to evaluate whether S1P serum titers are altered in food allergic children and if the S1P levels correlate with the outcome of anaphylaxis during double blind placebo controlled food challenges (DBPCFCs).
Conditions
Timeline
- Start date
- 2011-12-01
- Primary completion
- 2017-01-01
- Completion
- 2017-01-01
- First posted
- 2013-01-28
- Last updated
- 2015-12-11
Locations
1 site across 1 country: Austria
Source: ClinicalTrials.gov record NCT01776489. Inclusion in this directory is not an endorsement.